Back to results
US 6,932,972 B2Granted
Combined vaccine compositions
AssigneeSmithKline Beecham Biologicals s.a.
InventorsJean Stephenne, Martine Anne Cecile Wettendorff
Life of this patent
Estimating the term…
Abstract
Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, an HPV antigen, a V2V antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.
Claims8
A vaccine composition comprising:
- (a) a hepatitis B surface antigen (HBsAg) for inducing an immunoprotective response;
- and
- (b) a herpes simplex glycoprotein D (HSV gD) antigen or a truncate thereof, wherein the truncate comprises amino acids 1-306 of a naturally occuring glycoprotein D, for inducing an immunoprotective response,
- in conjunction with an adjuvant which is a preferential stimulator of TH 1 cell response wherein the HBsAg antigen and the HSV gD antigen are not covalently linked to each other.
1 more element
Dependencies are inferred from the claim text.